• Cancel
    Date:2018-03

    CEC Capital Served as Exclusive Financial Advisor

  • Cancel
    Date:2018-03

    CEC Capital Served as Exclusive Financial Advisor

  • Cancel
    Date:2018-02

    CEC Capital Served as Exclusive Financial Advisor

  • Cancel
    Date:2018-02

    CEC Capital Served as Exclusive Financial Advisor

  • Cancel
    Date:2017-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=329

    December 25, 2017- Suning Financial Services, a subsidiary of Suning Commerce Group(002024.SZ), announced today that it had entered into definitive agreements to raise a more than RMB5.3 billion. The round will be led by Suning Holdings, YF Capital, and GP Capital, with participation from CICC, China Everbright Investment, and SCGC, etc. for a total equity stake of 16.5% of the company.

  • Cancel
    Date:2017-11
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=327

    3D Medicines, Chinese leading cancer-targeted theranostic platform company, has raised ¥670 million in a new funding round recently. The round was led by the State-Controlled Venture Capital Fund mainly sponsored by China Reform Holdings Corporation LTD.

  • Cancel
    Date:2017-11
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=325

    Zensun Sci & Tech (871392.OC), a leading innovative drug developer in China, announced an impressive RMB 507 million financing round yesterday, led by SDIC Venture Capital Management Co., Ltd., with a host of new backers including Tianfeng Tianrui Investm

  • Cancel
    Date:2017-11
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=324

    Cygnus Biosciences (Beijing) Co., Ltd., a leading domestic company focusing on developing local High-Throughput DNA sequencing platform, announced its Series B financing of RMB 130 million which was jointly led by Oriental Yirui (Shanghai) Fund and the Zh

  • Cancel
    Date:2017-11

    CEC Capital Served as Exclusive Financial Advisor